Hepatocellular carcinoma in patients with HCV

Research output: Contribution to journalArticle

Abstract

In most Western countries hepatitis C virus (HCV) is a common risk factor for hepatocellular carcinoma (HCC). Many HCCs are multifocal in origin, but HCC may also grow as a single hepatic nodule for years before generating satellite or distant tumours. HCV may promote cancer through cirrhosis, which is often associated with HCV-related HCC, but it might also have oncogenic properties by interacting with cellular genes that regulate cell growth and differentiation. Treatment of patients with chronic hepatitis C using interferon might attenuate HCC risk, particularly in those who respond to therapy. Many patients whose cancer is detected early have been successfully treated by liver transplantation and have shown significantly prolonged survival. This is less often achieved with hepatic resection or regional therapies, which may indeed destroy small tumours, without affecting the complications of portal hypertension. Screening remains the only realistic approach for improving the treatment of HCC patients, but its cost-effectiveness is uncertain.

Original languageEnglish
Pages (from-to)327-339
Number of pages13
JournalBailliere's Best Practice and Research in Clinical Gastroenterology
Volume14
Issue number2
DOIs
Publication statusPublished - Apr 2000

Fingerprint

Hepacivirus
Hepatocellular Carcinoma
Neoplasms
Liver
Portal Hypertension
Chronic Hepatitis C
Therapeutics
Liver Transplantation
Interferons
Cost-Benefit Analysis
Cell Differentiation
Fibrosis
Survival
Growth
Genes

Keywords

  • Cirrhosis
  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Interferon
  • Liver transplantation
  • Screening

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatocellular carcinoma in patients with HCV. / Colombo, Massimo.

In: Bailliere's Best Practice and Research in Clinical Gastroenterology, Vol. 14, No. 2, 04.2000, p. 327-339.

Research output: Contribution to journalArticle

@article{7686569f59a54e63ab43ee8335ea2bae,
title = "Hepatocellular carcinoma in patients with HCV",
abstract = "In most Western countries hepatitis C virus (HCV) is a common risk factor for hepatocellular carcinoma (HCC). Many HCCs are multifocal in origin, but HCC may also grow as a single hepatic nodule for years before generating satellite or distant tumours. HCV may promote cancer through cirrhosis, which is often associated with HCV-related HCC, but it might also have oncogenic properties by interacting with cellular genes that regulate cell growth and differentiation. Treatment of patients with chronic hepatitis C using interferon might attenuate HCC risk, particularly in those who respond to therapy. Many patients whose cancer is detected early have been successfully treated by liver transplantation and have shown significantly prolonged survival. This is less often achieved with hepatic resection or regional therapies, which may indeed destroy small tumours, without affecting the complications of portal hypertension. Screening remains the only realistic approach for improving the treatment of HCC patients, but its cost-effectiveness is uncertain.",
keywords = "Cirrhosis, Hepatitis C virus, Hepatocellular carcinoma, Interferon, Liver transplantation, Screening",
author = "Massimo Colombo",
year = "2000",
month = "4",
doi = "10.1053/bega.1999.0079",
language = "English",
volume = "14",
pages = "327--339",
journal = "Bailliere's Best Practice and Research in Clinical Gastroenterology",
issn = "1521-6918",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Hepatocellular carcinoma in patients with HCV

AU - Colombo, Massimo

PY - 2000/4

Y1 - 2000/4

N2 - In most Western countries hepatitis C virus (HCV) is a common risk factor for hepatocellular carcinoma (HCC). Many HCCs are multifocal in origin, but HCC may also grow as a single hepatic nodule for years before generating satellite or distant tumours. HCV may promote cancer through cirrhosis, which is often associated with HCV-related HCC, but it might also have oncogenic properties by interacting with cellular genes that regulate cell growth and differentiation. Treatment of patients with chronic hepatitis C using interferon might attenuate HCC risk, particularly in those who respond to therapy. Many patients whose cancer is detected early have been successfully treated by liver transplantation and have shown significantly prolonged survival. This is less often achieved with hepatic resection or regional therapies, which may indeed destroy small tumours, without affecting the complications of portal hypertension. Screening remains the only realistic approach for improving the treatment of HCC patients, but its cost-effectiveness is uncertain.

AB - In most Western countries hepatitis C virus (HCV) is a common risk factor for hepatocellular carcinoma (HCC). Many HCCs are multifocal in origin, but HCC may also grow as a single hepatic nodule for years before generating satellite or distant tumours. HCV may promote cancer through cirrhosis, which is often associated with HCV-related HCC, but it might also have oncogenic properties by interacting with cellular genes that regulate cell growth and differentiation. Treatment of patients with chronic hepatitis C using interferon might attenuate HCC risk, particularly in those who respond to therapy. Many patients whose cancer is detected early have been successfully treated by liver transplantation and have shown significantly prolonged survival. This is less often achieved with hepatic resection or regional therapies, which may indeed destroy small tumours, without affecting the complications of portal hypertension. Screening remains the only realistic approach for improving the treatment of HCC patients, but its cost-effectiveness is uncertain.

KW - Cirrhosis

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Interferon

KW - Liver transplantation

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=0034124475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034124475&partnerID=8YFLogxK

U2 - 10.1053/bega.1999.0079

DO - 10.1053/bega.1999.0079

M3 - Article

C2 - 10890325

AN - SCOPUS:0034124475

VL - 14

SP - 327

EP - 339

JO - Bailliere's Best Practice and Research in Clinical Gastroenterology

JF - Bailliere's Best Practice and Research in Clinical Gastroenterology

SN - 1521-6918

IS - 2

ER -